E.01REFUTES
No Safety Signal
FDA cited lack of data, not adverse events. No documented safety crisis triggered the removals.
PEPTIDE MYTHBUSTER
Following the money behind regulatory decisions
Verdict:BUSTED
FDA BANNED PEPTIDES FOR SAFETY
Myth #003 / Analysis
01 / The Claim
WHAT PEOPLE SAY
"The FDA removed peptides from compounding because they're dangerous and were harming people — it was a public health decision, plain and simple.
02 / Evidence
THE DATA
Each point of evidence assessed against the original claim.
E.02REFUTES
Suspicious Timing
Ban finalized weeks before Eli Lilly's tirzepatide approval. Compounded versions cost 80-90% less.
E.03REFUTES
Active Litigation
Outsourcing Facilities Association and compounding pharmacies have filed federal lawsuits challenging the decision.
E.04REFUTES
Pharma Lobbying
Brand-name manufacturers spent $374 million lobbying Congress in 2023. Compounding pharmacies spent under $2 million.
E.05REFUTES
Historical Pattern
Similar removals preceded other branded drug launches. Pattern suggests market clearing, not safety enforcement.
E.06SUPPORTS
Some Valid Concerns
Compounding quality does vary. Sterility and dosing consistency are legitimate regulatory interests.
E.07NEUTRAL
Data Gap Reality
Many peptides lack large-scale trials. Absence of safety data isn't proof of safety.
03 / Verdict
THE RULING
No safety crisis preceded the ban. Timing suggests market protection for newly-approved branded drugs, not consumer safety.
04 / Key Facts
THE SCIENCE
ZERO DEATHS
No fatalities or serious adverse events from compounded peptides were cited in the FDA's removal justification.
$1,060 VS $50
Monthly cost of branded tirzepatide versus compounded versions. The price gap explains the lobbying intensity.
17 PEPTIDES
Number of compounds removed from the 503A bulk list in a single regulatory action — unprecedented scope.
FEDERAL LAWSUITS
Multiple legal challenges argue the FDA violated administrative procedure and acted arbitrarily.
05 / Deep Dive
WHY IT MATTERS
The FDA removed 17 peptides from the 503A bulking list in late 2023, citing insufficient safety data — not documented harm. This happened weeks before tirzepatide (Zepbound) hit the market at $1,060/month. Multiple lawsuits now challenge the decision, arguing the real motive was eliminating cheaper compounded competition.
06 / Sources
REFERENCES
- [01]
Feldman, R. & Frondorf, E. (2017). Drug Wars: How Big Pharma Raises Prices and Keeps Generics off the Market. Cambridge University Press.
- [02]
Carrier, M.A. & Shadowen, S.D. (2016). Product Hopping: A New Framework. Notre Dame Law Review.
View Source - [03]
FDA Center for Drug Evaluation (2023). Bulk Drug Substances Used in Compounding Under Section 503A. Federal Register.
View Source - [04]
Outsourcing Facilities Association (2024). OFA v. FDA: Complaint for Declaratory and Injunctive Relief. U.S. District Court.
- [05]
Wouters, O.J., Kanavos, P.G. & McKee, M. (2017). Comparing Generic Drug Markets in Europe and the United States. Milbank Quarterly.
View Source
regulationcompoundingtirzepatideFDAmarket-access
Peptide Mythbuster. Evidence-based analysis.
Back to All Myths